{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T14:51:27Z","timestamp":1791816687400,"version":"4.3.4"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T00:00:00Z","timestamp":1699401600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Katalin Karik\u00f3 and Drew Weissman were given the 2023 Nobel Prize in Physiology or Medicine for their findings of nucleoside base modifications that lead to the development of effective mRNA vaccines against COVID-19. This was a remarkable achievement, given that their initial manuscript was rejected by Nature and Science in 2005. The development of mRNA vaccines lagged for more than a decade for several reasons, including the lack of funding, the perceived risks of the technology, and the scepticism of many scientists. Furthermore, Karik\u00f3 and Weissman\u2019s study appeared to be technical and difficult to understand. The COVID-19 pandemic, on the other hand, has shown the importance of mRNA vaccine technology. COVID-19 mRNA vaccines have been highly effective in preventing serious illness, hospitalization, and death. The Nobel Prize for Karik\u00f3 and Weissman highlights the importance of perseverance, diversity, and inclusion in translational immunology. We need to build a more inclusive scientific community, where scientists from all backgrounds are supported and their work is valued. This will result in more scientific breakthroughs and better healthcare for everyone.<\/jats:p>","DOI":"10.3389\/fimmu.2023.1306025","type":"journal-article","created":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T16:14:39Z","timestamp":1699546479000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":24,"title":["From rejection to the Nobel Prize: Karik\u00f3 and Weissman\u2019s pioneering work on mRNA vaccines, and the need for diversity and inclusion in translational immunology"],"prefix":"10.3389","volume":"14","author":[{"given":"Amit","family":"Bansal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,11,8]]},"reference":[{"key":"B1","unstructured":"Press Release: The Nobel Assembly at Karolinska Institutet2023"},{"key":"B2","unstructured":"Nobel Prize Awarded to Covid Vaccine Pioneers2023"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2005.06.008","article-title":"Suppression of Rna recognition by toll-like receptors: the impact of nucleoside modification and the evolutionary origin of Rna","volume":"23","author":"Kariko","year":"2005","journal-title":"Immunity"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2008.200","article-title":"Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability","volume":"16","author":"Kariko","year":"2008","journal-title":"Mol Ther"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkq347","article-title":"Incorporation of pseudouridine into mRNA enhances translation by diminishing pkr activation","volume":"38","author":"Anderson","year":"2010","journal-title":"Nucleic Acids Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvacx.2023.100262","article-title":"Durable immune responses after bnt162b2 vaccination in home-dwelling old adults","volume":"13","author":"Hansen","year":"2023","journal-title":"Vaccine X"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2023.1164326","article-title":"Risk assessment and antibody responses to Sars-Cov-2 in healthcare workers","volume":"11","author":"Bansal","year":"2023","journal-title":"Front Public Health"},{"key":"B8","unstructured":"Uk Authorises Pfizer\/Biontech Covid-19 Vaccine2020"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.2598","article-title":"Estimation of Covid-19 mRNA vaccine effectiveness and Covid-19 illness and severity by vaccination status during omicron Ba.4 and Ba.5 sublineage periods","volume":"6","author":"Link-Gelles","year":"2023","journal-title":"JAMA Netw Open"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0276759","article-title":"Effectiveness of Covid-19 vaccines (Covishieldtm and covaxin (R)) in healthcare workers in Mumbai, India: A retrospective cohort analysis","volume":"17","author":"Contractor","year":"2022","journal-title":"PLoS One"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02000-6","article-title":"Efficacy, safety, and lot-to-lot immunogenicity of an inactivated Sars-Cov-2 vaccine (Bbv152): interim results of a randomised, double-blind, controlled, phase 3 trial","volume":"398","author":"Ella","year":"2021","journal-title":"Lancet"},{"key":"B12","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.ijid.2022.07.033","article-title":"Effectiveness of Bbv152\/Covaxin and Azd1222\/Covishield vaccines against severe Covid-19 and B.1.617.2\/delta variant in India, 2021: A multi-centric hospital-based case-control study","volume":"122","author":"Bhatnagar","year":"2022","journal-title":"Int J Infect Dis"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107715","article-title":"Effectiveness of an inactivated Sars-Cov-2 vaccine in Chile","volume":"385","author":"Jara","year":"2021","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1186\/s12916-022-02509-8","article-title":"Vaccine Effectiveness against Referral to Hospital after Sars-Cov-2 Infection in St. Petersburg, Russia, During the Delta Variant Surge: A Test-Negative Case-Control Study","volume":"20","author":"Barchuk","year":"2022","journal-title":"BMC Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines3020373","article-title":"Influenza vaccination strategies: comparing inactivated and live attenuated influenza vaccines","volume":"3","author":"Sridhar","year":"2015","journal-title":"Vaccines (Basel)"},{"key":"B16","unstructured":"Covid-19 Vaccine2023"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(22)00320-6","article-title":"Global impact of the first year of Covid-19 vaccination: A mathematical modelling study","volume":"22","author":"Watson","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"B18","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1093\/cid\/ciac803","article-title":"Safety and efficacy of the Nvx-Cov2373 coronavirus disease 2019 vaccine at completion of the placebo-controlled phase of a randomized controlled trial","volume":"76","author":"Heath","year":"2023","journal-title":"Clin Infect Dis"},{"key":"B19","doi-asserted-by":"crossref","unstructured":"CallawayE\n            NaddafM\n          Pioneers of mRNA Covid Vaccines Win Medicine Nobel2023","DOI":"10.1038\/d41586-023-03046-x"},{"key":"B20","unstructured":"Why We Need to Increase Diversity in the Immunology Research Community2020"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-019-0470-6","article-title":"Why we need to increase diversity in the immunology research community","volume":"20","author":"Iwasaki","year":"2019","journal-title":"Nat Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.966193","article-title":"For us by us: instituting mentorship models that credit minoritized medical faculty expertise and lived experience","volume":"9","author":"Bath","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"B23","unstructured":"All Nobel Prizes in Physiology or Medicine2023"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaa737","article-title":"Sars-Cov-2-specific neutralizing antibody responses in norwegian health care workers after the first wave of Covid-19 pandemic: A prospective cohort study","volume":"223","author":"Trieu","year":"2021","journal-title":"J Infect Dis"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01433-3","article-title":"Long Covid in a prospective cohort of home-isolated patients","volume":"27","author":"Blomberg","year":"2021","journal-title":"Nat Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2020.100014","article-title":"Attack rates amongst household members of outpatients with confirmed Covid-19 in Bergen, Norway: A case-ascertained study","volume":"3","author":"Kuwelker","year":"2021","journal-title":"Lancet Reg Health Eur"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1306025\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T16:14:41Z","timestamp":1699546481000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1306025\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,8]]},"references-count":26,"alternative-id":["10.3389\/fimmu.2023.1306025"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1306025","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,8]]},"article-number":"1306025"}}